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N ATURAL xenophile antibodies (NXA) and graft-induced xenophile antibodies (GIXA) are consid-
ered major barriers to organ transplantation between phy-
logenetically discordant species. I Thus, major efforts to 
achieve successful xenotransplantation must aim at (a) the 
elimination of NXA from the recipient's serum and (b) 
efficient inhibition of subsequent GIXA production after 
xenogeneic sensitization. This study investigates the ef-
fects of a time-limited treatment consisting of xenogeneic 
antigen (AG) plus short-term cyclophosphamide (CY) in 
the model "human-to-rat" to eliminate preexisting NXA 
and to inhibit graft-dependent GIXA production. This 
approach is based on previous studies in our laboratory2, 
in which B-lymphocyte tolerance was experimentally 
achieved in rats by applying CY at the most vulnerable 
phase of cell proliferation, that is , during xenogeneic 
sensitization. The principles of this concept are presently 
being successfully applied in the clinic by treating severe 
forms of autoimmune diseases , such as systemic lupus 
erythematosus. 3 
MATERIALS AND METHODS 
Animals 
Lewis rats (3-month-old females; MHC:RTI ') received 5 x 106 
human peripheral blood lymphocytes (PBL) as xenogeneic AG 
intraperitoneally either on day 0 or on day 0 plus day 30. Cy was 
applied at a dosage of20 mg/kg for 6 days, (a) from day 0 until day 
5 or (b) additionally from day 30 until day 35. The total dosage of 
120 mg/kg represented approximately 65% LDso. 
Experimental Design 
The experimental design consisted of four treatment groups: 
group I received CY from day 0 until day 5; group 2 received a 
single application of xenogeneic AG on day 0; group 3 received 
AG on day 0 and CY from day 0 until day 5, whereas group 4 was 
additionally treated with AG on day 30 and with CY from day 30 
until day 35. Tail vein blood was collected at 10-day intervals for 
analysis ofNXA and GIXA by standard flow cytometry (FACS). 
Determination of NXA and GIXA in 
Indirect Immunofluorescence 
Rat sera were diluted I :2, I :4, 1:8, etc for the determination of 
IgM and IgG antibody titers in indirect immunofluorescence 
(FACS) using human PBL as target cells (Fig I). Secondary 
antibodies were (a) fluorescein (DTAF)-conjugated, AffinePure 
goat anti-rat IgG, Fc fragment specific (cat. no. 112-015-071, 
Dianova, Hamburg, Germany), and (b) fluorescein (DTAF)-con-
jugated AffinePure F(ab')2 fragment goat anti-rat IgM, Mu chain 
specific (cat. no. 112-016-075, Dianova) . The titer was determined 
by the highest serum dilution at which 90% or more antibody 
binding was observed above background fluorescence. 
! ! 
Negati ve C~ntrol 
Fig 1. Analysis of NXA and GIXA (previously called IXA) by flow 
cytometry (FACS) and determination of antibody titers. (Top left) 
Negative control. (Top right) Example of an NXA- or a GIXA-
positive rat serum. (Bottom left) Titration of an NXA- or a 
GIXA-positive rat serum. (Bottom right) R1 = human PBL, which 
served as target cells. 
Specificity Control 
To teSt for the specificity of suppressive effects after combined 
treatment, selective rat sera were comparatively tested on human, 
porcine, and fish (trout) target cells. 
RESULTS 
NXA Reduction by CY (Group 1) 
To test whether it is possible to suppress the production of 
NXA in nongrafted animals, normal, that is, unsensitized 
Lewis rats received CY from day 0 to day 5 (n = 5). The 
result of this experiment is documented in Fig 2 and can be 
summarized as follows: the CY treatment significantly 
inhibits NXA production. However, the inhibition is re-
versible and lasts only as long as CY is effective in vivo. 
GIXA Induction by Xenoantigen (Group 2) 
The following experiment was designed to establish the 
relevant positive control in our model "human-to-rat" for 
a subsequent manipUlation ofNXA and GIXA production. 
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Fig 2. NXA reduction by CY (group 1). Normal, that is, unsensi-
tized Lewis rats received CY from day 0 to day 5 (n = 5 per day) . 
Normal Lewis rats received a single injection of AG on day 
o (n = 5). The result is documented in Fig 3 and can be 
summarized as follows : the production of GIXA strongly 
increases and , as expected , switches from IgM to IgG 
isotype. This xenogeneic sensitization effect lasts for a 
long period of time . 
NXAlGIXA Reduction by Xenoantigen and CY (Group 3) 
To answer the question, whether a time-limited combined 
treatment, consisting of AG and CY is capable of suppress-
ing not only GIXA, but also NXA, Lewis rats were treated 
. with AG on day 0 and with CY from day 0 to day 5 (n = 5). 
The results of this experiment are documented in Fig 4 and 
can be summarized as follows. (a) Effects of the combined 
treatment of NXA (in comparison with group 1, see Fig 2) : 
NXA-IgM are significantly reduced, whereas the com-
bined treatment has no significant effect on NXA-IgG. (b) 
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Fig 4. NXAlGIXA reduction by xenoantigen and CY (group 3) . 
Lewis rats were treated with AG on day 0 and with CY from day 0 
to day 5 (n = 5 per day) . 
Effects of the combined treatment on GIXA (in compari-
son with group 2, see Fig 3): Both GIXA-IgM and GIXA-
IgG are strongly reduced until day 90. 
NXAlGIXA Suppression by Repeated Xenoantigen and CY 
(Group 4) 
To test whether the above observed NXA and GIXA 
reduction could be intensified to "suppression," the com-
bined treatment, AG plus CY, was repeated on day 30 (n = 
5). The result of this experiment is documented in Fig 5 
and can be summarized as follows . (a) Effects of the 
repeated combined treatment on NXA (in comparison with 
group I, see Fig 2): NXA-IgM are suppressed beyond day 
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Fig 5. NXAlGIXA suppression by repeated xenoantigen and CY 
(group 4). In this group the combined treatment was repeated on 
day 30 (n = 5 per day). 
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100, NXA-IgG are suppressed until day 60. (b) Effects of 
the repeated combined treatment on GIXA (in comparison 
with group 2, see Fig 3): GIXA-IgM are suppressed 
beyond day 100. GIXA-IgG are suppressed until day 60, 
and are strongly reduced beyond day 100. 
Specificity Control 
To test whether the suppressive effects obtained by com-
bined and repeated combined treatment are xenoantigen 
specific, rat sera from experimental group 3 (collected on 
day 30) and from group 4 (collected on day 60) were tested 
comparatively on human, porcine, and fish (trout) PBL 
target cells (n = 5). NXAlGIXA positive sera of experi-
mental group 2 served as positive control. The result is not 
documented but can be summarized as follows: (a) Spec-
ificity control with porcine target cells: antibody binding 
on porcine target cells was similarly strongly suppressed as 
on human target cells. It is suggested that this nonspeci-
ficity with regard to two different mammalian species was 
due to a crossreactivity of GIXA on human and porcine 
PBL target epitopes. (b) Specificity control with fish target 
cells: in contrast to the above finding, antibody binding on 
fish PBL was not suppressed, thus indicating specificity of 
immunosuppression. This experiment clearly documents 
that the combined treatment is capable of inducing xenoan-
tigen-specific B-lymphocyte tolerance. 
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CONCLUSIONS 
Our data indicate that a time-limited combined 
consisting of xenoantigen and CY, and in particular 
repetition of this treatment protocol, appears to be a ' 
effective new approach to downregulate the - .... w,'uv 
mediated primary xenograft rejection. This holds not 
for GIXA but also for NXA, which are responsible 
mediating hyperacute graft rejection. Unlike CY alone 
combination of both parameters, AG plus CY, ' 
long-lasting specific unresponsiveness, that is, lUH;rallC'e' 
against the sensitizing xenoantigen. The advantage of 
approach with regard to a possible clinical application 
be that CY is applied in a time-limited fashion rather 
given permanently . 
ACKNOWLEDGMENTS 
The authors would like to thank Mrs K. Dohm, Ms C. Gier, Ms ' 
Prien, Mrs H. Steifen, and Mrs I. Wertz-Steinke for exceUent 
technical assistance and Dr Rolf Siewing for kindly providing u~ 
with trout PBL. 
REFERENCES 
1. Milgrom F: In Hardy MA (ed). Xenograft 25. Amsterdam: 
Excerpta Medica, 1989, p 149 
2. Herrlinger JD, MiiJler-Ruchholtz W: Z Immun Forsch 146: 
195, 1973 
3. Schroeder JO, Euler HH: Adv Exp Med Bioi 260:203,1989 
